

# WP2 Development of study tools

## Objectives

WP2 develops tools that to be used in WP7 for the development of protocols and the conduct of studies. After a complete review and discussion of the potential confounders and sources of bias already published, WP2 is in charge of developing tools to facilitate the implementation of the studies, such as development of applications to support the studies, i.e. protocol templates, facilitate site selection, informed consent, collect data uniformly, etc. Guidelines to identify and select study sites with different vaccine types, guidelines for identification of vaccine status and for the feasibility of using laboratory tools, will be developed and evaluated through the different annual studies.

## WP leaders

**FISABIO and GSK**

## Partners involved

**FISABIO, INSERM, P95, UNIFI, SYNAPSE, THL, ISS, SURREY, UCBL, SP, ABBOT, SEQIRUS, GSK, OPBG**